Quality Control– tag –
-
The Medicine Maker Forecasts Commercial-Scale iPSC Cell Therapy Hinges on Allogeneic Advances and Manufacturing Bottleneck Resolution
The Medicine Maker UK Overview The Medicine Maker reports that commercial-scale iPSC cell therapy hinges on the evolution of allogeneic cell therapies and the resolution of manufacturing bottlenecks. Stefan Braam, CTO of Cellistic, discu... -
KOLON Biotech Boosts End-to-End CDMO Services for Advanced Cell, Gene, and Exosome Therapies in South Korea
MTEC South Korea Overview South Korea's KOLON Biotech is enhancing its comprehensive CDMO services, specializing in advanced cell, gene, and exosome therapies. The company offers end-to-end solutions, from technology transfer and process... -
Yeasen and Porton Advanced Form Strategic Alliance to Fortify CGT Supply Chain and Drive Innovation
Company Announcement China Overview Yeasen Biotechnology and Porton Advanced Solutions have established a strategic partnership aimed at fortifying the cell and gene therapy (CGT) supply chain and fostering innovation. The alliance will ... -
Liv Hospital Charts Course for Scalable CAR-T Production with Comprehensive GMP and Bioreactor Guide
Liv Hospital Turkey Overview Liv Hospital has released a comprehensive guide detailing the critical, GMP-compliant manufacturing process for CAR-T cell therapies, from T-cell collection and genetic modification to controlled expansion in... -
Liv Hospital Details Advanced ‘Off-the-Shelf’ CAR-T Manufacturing, Promising Scalability and Broader Access
Liv Hospital Turkey Overview Liv Hospital has unveiled its detailed manufacturing process for allogeneic, 'off-the-shelf' CAR-T cell therapy, a significant leap towards overcoming the logistical and cost barriers of current personalized ... -
CSPC Pharmaceutical and AstraZeneca Form Joint Venture for AI-Driven GMP Biologics Manufacturing Facility in China
BioPharm International China Overview CSPC Pharmaceutical Group and AstraZeneca have signed a joint venture agreement to construct a next-generation biopharmaceutical manufacturing facility in Shijiazhuang, China. This facility aims to i... -
AI Drives Strategic Advancement in Biopharmaceutical Development: From Antibody Design to Quality Control, Backed by Indian Government Initiatives
Press Information Bureau, Government of India India Overview AI is strategically transforming biopharmaceutical development, from target identification and multispecific antibody design to automated quality control. India is significantl... -
Liv Hospital Advances iPSC Reprogramming, Sets Sights on Scalable Production for Regenerative Medicine
Liv Hospital Turkey Overview Liv Hospital's latest research details critical optimizations in induced pluripotent stem cell (iPSC) reprogramming, emphasizing advanced gene delivery systems and optimal vector selection for efficient and s... -
Liv Hospital Highlights Off-the-Shelf Allogeneic CAR-T Manufacturing for Enhanced Accessibility via Standardized Donor Cells
Liv Hospital Turkey Overview Liv Hospital is championing the development of allogeneic CAR-T cell manufacturing as an 'off-the-shelf' solution, leveraging standardized donor cells to significantly improve treatment accessibility. This ad... -
APAC’s Biomanufacturing Ascent: Australia Pioneers Viral Vector Production for Gene Therapies
Industry Publication Australia Overview The Asia-Pacific (APAC) region is rapidly accelerating its specialized manufacturing capabilities for high-value modalities like viral vectors and cell therapies, moving beyond traditional API prod...
